TP53 and hepatocellular carcinoma: Whole-exome sequencing, RNA sequencing, and computational bioinformatics revealed that TP53-specific neoantigens in HCC patients were associated with longer OS and enhanced anti-tumor immunity, characterized by higher immune scores, increased cytotoxic lymphocyte infiltration, and higher cytolytic activity scores [71].